首页 > 最新文献

Laboratory Investigation最新文献

英文 中文
Tumor-Infiltrating Lymphocyte Aggregation Refines Prognosis in Patients With Hepatocellular Carcinoma 肿瘤浸润性淋巴细胞聚集改善肝细胞癌患者预后。
IF 4.2 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-11-25 DOI: 10.1016/j.labinv.2025.104267
Zehong Zhang , Yuan’e Lian , Yijuan Wu , Zhongchang Weng , Jiaying Ye , Siqin Zhang , Lianhuang Li , Yannan Bai
The prognostic role of tumor-infiltrating lymphocytes (TILs) in hepatocellular carcinoma (HCC) remains elusive. This study explored the association between TIL aggregation in early-stage HCC tissues and patient survival. Individual patient-level data from 353 patients diagnosed with HCC who underwent radical hepatectomy were retrospectively analyzed. TIL aggregation was analyzed using an artificial neural network algorithm to define the immune phenotypes (IPs) within hematoxylin and eosin–stained whole-slide images. The association between TIL aggregation and survival was compared among IPs, and an optimized TIL phenotype was validated with clinical variables. Among the 8 IP features measured using the artificial neural network algorithm, TIL densityK50, a metric generated by an assigned density of each cell based on its distance with the 50 nearest lymphocytes, was associated with improved disease-free survival in univariate (hazard ratio, 0.282; 95% CI, 0.181-0.439; P < .0001) and multivariate analyses (hazard ratio, 0.315; 95% CI, 0.115-0.860; P = .024) after adjusting for clinical factors. When TIL densityK50 is combined with clinical factors (TIL-clinical–integrated [TCI] model), area under the curve performance for disease-free survival and overall survival was improved to 0.798 and 0.781 in the training cohort and 0.759 and 0.723 in the validation cohort, respectively. Furthermore, subgroup analyses indicated that its predictive value is particularly strong for very late recurrence and survival up to <8 years. Abundant TILs in HCC tissue are associated with reduced late recurrence risk and improved survival, suggesting a potential time-dependent prognostic role of TILs in early-stage HCC.
肿瘤浸润淋巴细胞(til)在肝细胞癌(HCC)中的预后作用仍然难以捉摸。本研究探讨了早期HCC组织中TIL聚集与患者生存之间的关系。回顾性分析了353例接受根治性肝切除术的HCC患者的个体数据。使用人工神经网络(ANN)算法分析TIL聚集情况,以确定苏木精和伊红染色全片图像中的免疫表型(IPs)。比较了不同IPs患者TIL聚集与生存之间的关系,并用临床变量验证了优化后的TIL表型。在使用人工神经网络算法测量的8个IP特征中,TIL密度k50(由每个细胞与最近的50个淋巴细胞的距离分配密度生成的度量)在单因素分析(风险比[HR], 0.282; 95%置信区间[CI],CI 0.181-0.439; P < 0.0001)和多因素分析(HR, 0.315; 95% CI, 0.115-0.860; P = 0.024)中与改善无病生存(DFS)相关。当TIL密度k50与临床因素(TIL- clinial - integrated model, TCI-model)相结合时,训练组DFS和总生存的AUC性能分别提高至0.798和0.781,验证组为0.759和0.723。此外,亚组分析表明,它对晚期复发和生存期< 8年的预测价值尤其强。HCC组织中大量的TILs与晚期复发风险降低和生存率提高相关,提示TILs在早期HCC中具有潜在的时间依赖性预后作用。
{"title":"Tumor-Infiltrating Lymphocyte Aggregation Refines Prognosis in Patients With Hepatocellular Carcinoma","authors":"Zehong Zhang ,&nbsp;Yuan’e Lian ,&nbsp;Yijuan Wu ,&nbsp;Zhongchang Weng ,&nbsp;Jiaying Ye ,&nbsp;Siqin Zhang ,&nbsp;Lianhuang Li ,&nbsp;Yannan Bai","doi":"10.1016/j.labinv.2025.104267","DOIUrl":"10.1016/j.labinv.2025.104267","url":null,"abstract":"<div><div>The prognostic role of tumor-infiltrating lymphocytes (TILs) in hepatocellular carcinoma (HCC) remains elusive. This study explored the association between TIL aggregation in early-stage HCC tissues and patient survival. Individual patient-level data from 353 patients diagnosed with HCC who underwent radical hepatectomy were retrospectively analyzed. TIL aggregation was analyzed using an artificial neural network algorithm to define the immune phenotypes (IPs) within hematoxylin and eosin–stained whole-slide images. The association between TIL aggregation and survival was compared among IPs, and an optimized TIL phenotype was validated with clinical variables. Among the 8 IP features measured using the artificial neural network algorithm, TIL density<sub>K50</sub>, a metric generated by an assigned density of each cell based on its distance with the 50 nearest lymphocytes, was associated with improved disease-free survival in univariate (hazard ratio, 0.282; 95% CI, 0.181-0.439; <em>P</em> &lt; .0001) and multivariate analyses (hazard ratio, 0.315; 95% CI, 0.115-0.860; <em>P</em> = .024) after adjusting for clinical factors. When TIL density<sub>K50</sub> is combined with clinical factors (TIL-clinical–integrated [TCI] model), area under the curve performance for disease-free survival and overall survival was improved to 0.798 and 0.781 in the training cohort and 0.759 and 0.723 in the validation cohort, respectively. Furthermore, subgroup analyses indicated that its predictive value is particularly strong for very late recurrence and survival up to &lt;8 years. Abundant TILs in HCC tissue are associated with reduced late recurrence risk and improved survival, suggesting a potential time-dependent prognostic role of TILs in early-stage HCC.</div></div>","PeriodicalId":17930,"journal":{"name":"Laboratory Investigation","volume":"106 1","pages":"Article 104267"},"PeriodicalIF":4.2,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145635287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Establishment and Multidimensional Characterization of a Novel Epstein-Barr Virus (EBV)–Negative Human Type I Natural Killer T-Cell Line NKT617 新型ebv阴性人Ⅰ型自然杀伤T细胞株NKT617的建立及多维特性研究
IF 4.2 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-11-25 DOI: 10.1016/j.labinv.2025.104266
Chencheng Li , Xixi Liu , Weiguang Zhang , Jing Yang , Xiaoli Zhang , Reaila Jianati , Pengjun Jiang , Fang Tian , Biqing Chen , Xuejun Zhu
Natural killer T cells (NKT), a unique subset of T lymphocytes, remain incompletely understood in terms of their development and functional regulation. Well-characterized immortalized cell lines are critical tools for investigating NKT cell biology in vitro. We established and maintained a novel NKT cell line, NKT617, derived from the peripheral blood of a patient with aggressive large granular lymphocyte leukemia. Cell morphology was assessed using scanning electron microscopy and transmission electron microscopy. Flow cytometry characterized the cell phenotype, whereas T-cell receptor (TCR) clonal gene rearrangement determined lineage. RNA sequencing compared gene expression profiles of NKT617 with other hematological tumor cell lines, such as natural killer (NK) cells, T cells, B cells, and monocytes. Tumorigenic potential was evaluated via in vitro colony formation assays and in vivo zebrafish xenograft models. NKT617 has been continuously cultured for >2 years, exceeding 100 passages, demonstrating monoclonal immortalization. It proliferates in a low-dose recombinant human interleukin-2–dependent manner and grows in suspension culture as single cells and aggregates. Flow cytometric analysis showed that NKT617 exhibits an NK-cell phenotype CD56+, CD158a+, NKp46+, membrane-bound CD3, and T-cell features cytoplasmic CD3+, CD2+, CD4+, CD8+, CD45RA+, and CD45RO+, with clonal TCRβ rearrangement. NKT617 was negative for B-cell and myeloid markers and positive for the TCRα chain (Vα24-Jα18), confirming its identity as a type I NKT cell. Transcriptome analysis showed shared markers with NK-cell and T-cell lines but a gene expression profile closer to NK cells. In vitro and in vivo assays confirmed its tumorigenic capacity. We report the first Epstein-Barr virus–negative human type I NKT cell line, NKT617, which offers significant potential for studying NKT cell development and advancing chimeric antigen receptor–based therapies. This cell line serves as a valuable tool for exploring NKT cell biology and developing targeted immunotherapies.
NKT细胞是T淋巴细胞的一个独特亚群,在其发育和功能调控方面仍不完全了解。具有良好特征的永生化细胞系是在体外研究NKT细胞生物学的关键工具。我们建立并维持了一种新的NKT细胞系NKT617,该细胞系来源于侵袭性大颗粒淋巴细胞白血病患者的外周血。用扫描电镜和透射电镜观察细胞形态。流式细胞术鉴定细胞表型,TCR克隆基因重排鉴定谱系。RNA测序比较了NKT617与其他血液肿瘤细胞系(如NK、T、B和单核细胞)的基因表达谱。通过体外集落形成试验和体内斑马鱼异种移植模型来评估其致瘤潜力。NKT617连续培养2年多,超过100代,实现了单克隆永生化。它以低剂量重组人il -2依赖性方式增殖,并以单细胞和聚集体的形式在悬浮培养中生长。流式细胞术分析显示,NKT617具有CD56+、CD158a+、Nkp46+、mCD3- NK细胞表型,T细胞具有cCD3+、CD2+、CD4+、CD8+、CD45RA+、CD45RO+的表型,克隆性TCRβ重排。NKT617对B细胞和髓系标志物呈阴性,对TCRα链(Vα24-Jα18)呈阳性,证实其为I型NKT细胞。转录组分析显示与NK和T细胞系共享标记,但基因表达谱更接近NK细胞。体外和体内实验证实了其致瘤能力。我们报道了第一个ebv阴性的人类I型NKT细胞系NKT617,它为研究NKT细胞发育和推进基于嵌合抗原受体的治疗提供了巨大的潜力。该细胞系为探索NKT细胞生物学和开发靶向免疫疗法提供了有价值的工具。
{"title":"Establishment and Multidimensional Characterization of a Novel Epstein-Barr Virus (EBV)–Negative Human Type I Natural Killer T-Cell Line NKT617","authors":"Chencheng Li ,&nbsp;Xixi Liu ,&nbsp;Weiguang Zhang ,&nbsp;Jing Yang ,&nbsp;Xiaoli Zhang ,&nbsp;Reaila Jianati ,&nbsp;Pengjun Jiang ,&nbsp;Fang Tian ,&nbsp;Biqing Chen ,&nbsp;Xuejun Zhu","doi":"10.1016/j.labinv.2025.104266","DOIUrl":"10.1016/j.labinv.2025.104266","url":null,"abstract":"<div><div>Natural killer T cells (NKT), a unique subset of T lymphocytes, remain incompletely understood in terms of their development and functional regulation. Well-characterized immortalized cell lines are critical tools for investigating NKT cell biology in vitro. We established and maintained a novel NKT cell line, NKT617, derived from the peripheral blood of a patient with aggressive large granular lymphocyte leukemia. Cell morphology was assessed using scanning electron microscopy and transmission electron microscopy. Flow cytometry characterized the cell phenotype, whereas T-cell receptor (TCR) clonal gene rearrangement determined lineage. RNA sequencing compared gene expression profiles of NKT617 with other hematological tumor cell lines, such as natural killer (NK) cells, T cells, B cells, and monocytes. Tumorigenic potential was evaluated via in vitro colony formation assays and in vivo zebrafish xenograft models. NKT617 has been continuously cultured for &gt;2 years, exceeding 100 passages, demonstrating monoclonal immortalization. It proliferates in a low-dose recombinant human interleukin-2–dependent manner and grows in suspension culture as single cells and aggregates. Flow cytometric analysis showed that NKT617 exhibits an NK-cell phenotype CD56<sup>+</sup>, CD158a<sup>+</sup>, NKp46<sup>+</sup>, membrane-bound CD3<sup>−</sup>, and T-cell features cytoplasmic CD3<sup>+</sup>, CD2<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>+</sup>, CD45RA<sup>+</sup>, and CD45RO<sup>+</sup>, with clonal TCRβ rearrangement. NKT617 was negative for B-cell and myeloid markers and positive for the TCRα chain (Vα24-Jα18), confirming its identity as a type I NKT cell. Transcriptome analysis showed shared markers with NK-cell and T-cell lines but a gene expression profile closer to NK cells. In vitro and in vivo assays confirmed its tumorigenic capacity. We report the first Epstein-Barr virus–negative human type I NKT cell line, NKT617, which offers significant potential for studying NKT cell development and advancing chimeric antigen receptor–based therapies. This cell line serves as a valuable tool for exploring NKT cell biology and developing targeted immunotherapies.</div></div>","PeriodicalId":17930,"journal":{"name":"Laboratory Investigation","volume":"106 1","pages":"Article 104266"},"PeriodicalIF":4.2,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145635203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative Evaluation of Antibody-Oligonucleotide Conjugation Strategies for Multiplexed Imaging Applications 多路成像应用中抗体-寡核苷酸偶联策略的比较评价。
IF 4.2 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-11-19 DOI: 10.1016/j.labinv.2025.104262
Chiara Caraccio , Josie van de Klashorst , Shelby Cherkas , Sara Ancel , Tim Noah Kempchen , Gustavo Vazquez , Yury Goltsev , Yu Xin Wang , Garry P. Nolan , John W. Hickey
Antibody-oligonucleotide conjugates (AOCs) have emerged as versatile tools with applications spanning diagnostics, therapeutics, and high-dimensional imaging. One major application of these is in multiplexed imaging techniques, such as CO-Detection by indEXing, which allow for the visualization of tissue networks at the single-cell level. In this study, we evaluated 4 methods—maleimide-modified, amine-modified, dibenzocyclooctyne (DBCO)-modified, and a site-specific enzyme-based method—to optimize the generation of AOCs for multiplexed imaging applications. Our assessment focused on key performance parameters, including conjugation efficiency, signal brightness, stability, reproducibility, and cost-effectiveness. Each conjugation chemistry proved effective, though the azide chemistry with DBCO oligonucleotides demonstrated more consistent conjugation success and stable signal retention over time. Compared with other protocols, this method produced reliably bright images and offered a more favorable cost profile, as further confirmed in a full-scale CO-Detection by indEXing multiplexed imaging experiment that yielded reproducible spatial data. The observed stability and reproducibility of the DBCO approach suggest that it may help reduce reagent waste and labor costs while facilitating the development of more comprehensive antibody panels. These findings indicate that the DBCO-modified oligonucleotide conjugation method is a valuable option for generating AOCs for multiplexed imaging and target current shortcomings, enabling more consistent, broader, and deeper multiplexed profiling.
抗体寡核苷酸偶联物(AOCs)已成为多功能工具,应用范围涵盖诊断、治疗和高维成像。这些技术的一个主要应用是多路成像技术,如成像共同检测(CODEX),它允许在单细胞水平上可视化组织网络。在这项研究中,我们评估了四种方法——马来酰亚胺修饰、胺修饰、dbco修饰和基于位点特异性酶的方法——来优化用于多路成像应用的AOCs的生成。我们的评估重点是关键性能参数,包括共轭效率、信号亮度、稳定性、再现性和成本效益。每种偶联化学都被证明是有效的,尽管与DBCO寡核苷酸的叠氮化物化学表现出更一致的偶联成功和稳定的信号保留。与其他方案相比,该方法产生了可靠的明亮图像,并提供了更有利的成本,这一点在全面的CODEX多路成像实验中得到了进一步证实,该实验产生了可重复的空间数据。观察到的DBCO方法的稳定性和可重复性表明,它可能有助于减少试剂浪费和人工成本,同时促进开发更全面的抗体面板。这些发现表明,dbco修饰的寡核苷酸偶联方法是一种有价值的选择,可用于生成用于多路成像的aoc,并针对当前的缺点,实现更一致、更广泛和更深的多路分析。
{"title":"Comparative Evaluation of Antibody-Oligonucleotide Conjugation Strategies for Multiplexed Imaging Applications","authors":"Chiara Caraccio ,&nbsp;Josie van de Klashorst ,&nbsp;Shelby Cherkas ,&nbsp;Sara Ancel ,&nbsp;Tim Noah Kempchen ,&nbsp;Gustavo Vazquez ,&nbsp;Yury Goltsev ,&nbsp;Yu Xin Wang ,&nbsp;Garry P. Nolan ,&nbsp;John W. Hickey","doi":"10.1016/j.labinv.2025.104262","DOIUrl":"10.1016/j.labinv.2025.104262","url":null,"abstract":"<div><div>Antibody-oligonucleotide conjugates (AOCs) have emerged as versatile tools with applications spanning diagnostics, therapeutics, and high-dimensional imaging. One major application of these is in multiplexed imaging techniques, such as CO-Detection by indEXing, which allow for the visualization of tissue networks at the single-cell level. In this study, we evaluated 4 methods—maleimide-modified, amine-modified, dibenzocyclooctyne (DBCO)-modified, and a site-specific enzyme-based method—to optimize the generation of AOCs for multiplexed imaging applications. Our assessment focused on key performance parameters, including conjugation efficiency, signal brightness, stability, reproducibility, and cost-effectiveness. Each conjugation chemistry proved effective, though the azide chemistry with DBCO oligonucleotides demonstrated more consistent conjugation success and stable signal retention over time. Compared with other protocols, this method produced reliably bright images and offered a more favorable cost profile, as further confirmed in a full-scale CO-Detection by indEXing multiplexed imaging experiment that yielded reproducible spatial data. The observed stability and reproducibility of the DBCO approach suggest that it may help reduce reagent waste and labor costs while facilitating the development of more comprehensive antibody panels. These findings indicate that the DBCO-modified oligonucleotide conjugation method is a valuable option for generating AOCs for multiplexed imaging and target current shortcomings, enabling more consistent, broader, and deeper multiplexed profiling.</div></div>","PeriodicalId":17930,"journal":{"name":"Laboratory Investigation","volume":"106 1","pages":"Article 104262"},"PeriodicalIF":4.2,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145573939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High Expression of CCL2 Correlated With Dendritic Cell Recruitment in Neuroblastomas Associated With Opsoclonus-Myoclonus Syndrome 高表达的ccl2与神经母细胞瘤中的树突状细胞募集相关,并伴有阵挛-肌阵挛综合征
IF 4.2 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-11-19 DOI: 10.1016/j.labinv.2025.104263
Maureen Voirin , Alexia Gazeu , Benoit Dumont , Aurélien Voissière , Léo Jannot , Dominique Plantaz , Nathalie Sturm , Nicolas Ber , Pascal Chastagner , Cécile Picard , Frédérique Dijoud , Christophe Caux , Nathalie Bendriss-Vermare , Hervé Sartelet
Neuroblastoma (NB) accounts for 10% to 15% of cancer-related deaths among children. In rare cases, NB is associated with opsoclonus-myoclonus syndrome (OMS), a neurological paraneoplastic syndrome. These low-risk (LR) NBs with OMS have a favorable prognosis and an immune-enriched microenvironment. The recruitment of dendritic cells (DCs) and T lymphocytes into tumors is known to be mediated by CCL2 and CXCL12, respectively. We investigated whether intratumor CCL2 and CXCL12 promote DC recruitment within the microenvironment of OMS-associated LR-NBs. We conducted a multicentric retrospective case-control study on 44 pediatric patients with NBs associated or not with OMS. The non-OMS population was subdivided into an LR-NB group versus a high-risk (HR)-NB group, with or without MYCN amplification. Immunohistochemistry was performed using anti-CCL2 and anti-CXCL12 antibodies. DC subpopulations were stained using OPAL spectral multiplex immunofluorescence. Immunostaining scores were established by semiquantitative optical analysis. Gene signatures of DC, as well as CCL2 and CXCL12 mRNA expressions, were also analyzed on a public RNA-Seq data set of NB. We observed a significantly higher protein expression of CCL2 in OMS-associated LR-NBs compared with MYCN-amplified HR-NBs, whereas CXCL12 was not preferentially expressed by any of the NB groups. Furthermore, DC infiltrate was more abundant in OMS-associated LR-NBs compared with any other NB risk groups and positively correlated with CCL2 expression. In silico analysis of public RNA-Seq data demonstrated a higher CCL2 expression in LR-NB with or without OMS compared with HR groups, and that the DC transcriptomic signature was higher in OMS-associated LR-NBs compared with HR-NB groups. We also observed a positive correlation between the DC gene signature and CCL2 or CXCL12 mRNA expression, to a lesser extent. Our results suggest that a DC-prone microenvironment might explain the favorable oncologic outcome of OMS-associated LR-NBs. CCL2 could be a therapeutic target to mobilize DCs in HR-NBs or in tumors characterized by a paucity of tumor-infiltrating DCs.
神经母细胞瘤(NB)占儿童癌症相关死亡的10%至15%。在极少数情况下,NB与眼阵挛-肌阵挛综合征(OMS)有关,这是一种神经副肿瘤综合征。这些低风险(LR) NB伴OMS预后良好,微环境免疫富集。树突状细胞(dc)和T淋巴细胞募集到肿瘤中分别是由CCL2和CXCL12介导的。我们研究了肿瘤内CCL2和CXCL12是否在OMS相关的lr - nb微环境中促进dc的募集。我们进行了一项多中心回顾性病例对照研究,对44例小儿NBs与OMS相关或不相关的患者进行了研究。非oms人群被细分为具有或不具有MYCN扩增的低风险NB组和高风险NB组。采用抗ccl2和抗cxcl12抗体进行免疫组化。使用OPAL光谱多重免疫荧光染色DC亚群。半定量光学分析建立免疫染色评分。在NB的公共RNAseq数据集上分析了DC以及CCL2和CXCL12 mRNA表达的基因特征。我们观察到,与MYCN扩增的hr -NB相比,OMS相关的lr -NB中CCL2的蛋白表达明显更高,而CXCL12在任何NB组中都没有优先表达。此外,与其他NB风险组相比,OMS相关的lr -NB中DC浸润更丰富,且与CCL2表达呈正相关。公开RNAseq数据的计算机分析显示,与HR组相比,有或没有OMS的LR-NB中CCL2表达更高,与HR- nb组相比,OMS相关的LR-NB中DCs转录组特征更高。我们还观察到DC基因特征与CCL2或CXCL12 mRNA表达之间存在较小程度的正相关。我们的研究结果表明,易发生DCs的微环境可能解释了OMS相关lr - nb的有利肿瘤预后。CCL2可能是动员hr - nb或以肿瘤浸润性dc缺乏为特征的dc的治疗靶点。
{"title":"High Expression of CCL2 Correlated With Dendritic Cell Recruitment in Neuroblastomas Associated With Opsoclonus-Myoclonus Syndrome","authors":"Maureen Voirin ,&nbsp;Alexia Gazeu ,&nbsp;Benoit Dumont ,&nbsp;Aurélien Voissière ,&nbsp;Léo Jannot ,&nbsp;Dominique Plantaz ,&nbsp;Nathalie Sturm ,&nbsp;Nicolas Ber ,&nbsp;Pascal Chastagner ,&nbsp;Cécile Picard ,&nbsp;Frédérique Dijoud ,&nbsp;Christophe Caux ,&nbsp;Nathalie Bendriss-Vermare ,&nbsp;Hervé Sartelet","doi":"10.1016/j.labinv.2025.104263","DOIUrl":"10.1016/j.labinv.2025.104263","url":null,"abstract":"<div><div>Neuroblastoma (NB) accounts for 10% to 15% of cancer-related deaths among children. In rare cases, NB is associated with opsoclonus-myoclonus syndrome (OMS), a neurological paraneoplastic syndrome. These low-risk (LR) NBs with OMS have a favorable prognosis and an immune-enriched microenvironment. The recruitment of dendritic cells (DCs) and T lymphocytes into tumors is known to be mediated by CCL2 and CXCL12, respectively. We investigated whether intratumor CCL2 and CXCL12 promote DC recruitment within the microenvironment of OMS-associated LR-NBs. We conducted a multicentric retrospective case-control study on 44 pediatric patients with NBs associated or not with OMS. The non-OMS population was subdivided into an LR-NB group versus a high-risk (HR)-NB group, with or without <em>MYCN</em> amplification. Immunohistochemistry was performed using anti-CCL2 and anti-CXCL12 antibodies. DC subpopulations were stained using OPAL spectral multiplex immunofluorescence. Immunostaining scores were established by semiquantitative optical analysis. Gene signatures of DC, as well as <em>CCL2</em> and <em>CXCL12</em> mRNA expressions, were also analyzed on a public RNA-Seq data set of NB. We observed a significantly higher protein expression of CCL2 in OMS-associated LR-NBs compared with <em>MYCN</em>-amplified HR-NBs, whereas CXCL12 was not preferentially expressed by any of the NB groups. Furthermore, DC infiltrate was more abundant in OMS-associated LR-NBs compared with any other NB risk groups and positively correlated with CCL2 expression. In silico analysis of public RNA-Seq data demonstrated a higher <em>CCL2</em> expression in LR-NB with or without OMS compared with HR groups, and that the DC transcriptomic signature was higher in OMS-associated LR-NBs compared with HR-NB groups. We also observed a positive correlation between the DC gene signature and <em>CCL2</em> or <em>CXCL12</em> mRNA expression, to a lesser extent. Our results suggest that a DC-prone microenvironment might explain the favorable oncologic outcome of OMS-associated LR-NBs. CCL2 could be a therapeutic target to mobilize DCs in HR-NBs or in tumors characterized by a paucity of tumor-infiltrating DCs.</div></div>","PeriodicalId":17930,"journal":{"name":"Laboratory Investigation","volume":"106 1","pages":"Article 104263"},"PeriodicalIF":4.2,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145574001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interassay Comparison With Digital Image Analysis of 4 Routine Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry Assays in Primary Breast Cancer and Its Metastasis 四种常规HER2免疫组化检测在原发性乳腺癌及其转移中的检测间比较与数字图像分析。
IF 4.2 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-11-19 DOI: 10.1016/j.labinv.2025.104261
Maaike Anna Hempenius , Mieke C. Zwager , Jeppe Thagaard , Lorian Slagter-Menkema , Henk J. Buikema , Ellis Barbé , Michael A. den Bakker , Marjolein G.J. Heerema , Elisabeth G.E. de Vries , Carolina P. Schröder , Nils A. ’t Hart , Bert van der Vegt
Trastuzumab-deruxtecan, an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2), improves overall survival in patients with breast cancer showing low or ultralow HER2 expression. Differences in HER2 test results have been reported between various HER2 assays and between primary tumors and metastases, but an objective comparison with incorporation of the new HER2-ultralow cutoff values is needed. This study aimed to assess the performance of 4 routine clinical-grade HER2 assays across and between primary tumors and their metastases using digital image analysis. Primary tumors and metastases from 193 patients with breast cancer who participated in the IMaging PAtients for Cancer drug selecTion—Metastatic Breast Cancer trial were incorporated into 6 tissue microarrays. Samples were stained by 4 laboratories using their routine HER2 immunohistochemistry protocols: 4B5 ultraView, 4B5 OptiView, SP3, and HercepTest (DG44). HER2 scores were determined using digital image analysis. The 4 HER2 assays showed significant differences in HER2 status in both primary tumors and metastases. Eighty-five matched primary tumors and metastases were analyzed to investigate concordance in HER2 status. Although no significant differences were found in HER2 scores between primary tumors and metastases for SP3 and both 4B5 assays, DG44 showed significantly higher HER2 scores in the metastasis (P = .004). Concordance between primary tumors and metastases was highest for 4B5 ultraView (69.4%), followed by SP3 (61.2%) and 4B5 OptiView (51.8%). DG44 showed the most variability, with only 36.5% of matched samples receiving the same HER2 category. DG44 identified a significantly higher proportion of HER2-(ultra)low cases and showed the most variability in HER2 status between matched primary tumors and metastases compared with 4B5 and SP3. The choice of HER2 assay can lead to discrepancies in HER2 status assessment, which could directly influence patient eligibility for trastuzumab-deruxtecan treatment.
曲妥珠单抗-德鲁西替康(T-DXd)是一种靶向人表皮生长因子受体2 (HER2)的抗体-药物偶联物,可提高HER2低或超低表达乳腺癌患者的总生存率。各种HER2检测方法之间以及原发肿瘤和转移瘤之间的HER2检测结果存在差异,但需要结合新的HER2超低临界值进行客观比较。本研究旨在利用数字图像分析(DIA)评估四种常规临床级HER2检测在原发肿瘤及其转移瘤之间和之间的表现。193名参与IMPACT-MBC试验的乳腺癌患者的原发肿瘤和转移瘤被纳入6个组织微阵列。4个实验室采用常规HER2免疫组化方案:4B5 ultraView、4B5 OptiView、SP3和HercepTest (DG44)对样品进行染色。采用DIA测定HER2评分。四项HER2检测显示,HER2在原发肿瘤和转移瘤中的状态存在显著差异。分析了85例匹配的原发肿瘤和转移瘤,以研究HER2状态的一致性。SP3和4B5检测中,原发肿瘤和转移瘤的HER2评分无显著差异,而DG44在转移瘤中的HER2评分明显较高(p = 0.004)。原发肿瘤与转移瘤的一致性在4B5 ultraView中最高(69.4%),其次是SP3(61.2%)和4B5 OptiView(51.8%)。DG44表现出最大的可变性,只有36.5%的匹配样本接受相同的HER2类别。与4B5和SP3相比,DG44鉴定出的HER2-(超低)低病例比例明显更高,并且在匹配的原发肿瘤和转移瘤之间显示出最大的HER2状态变异性。HER2检测的选择可能导致HER2状态评估的差异,这可能直接影响患者接受T-DXd治疗的资格。
{"title":"Interassay Comparison With Digital Image Analysis of 4 Routine Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry Assays in Primary Breast Cancer and Its Metastasis","authors":"Maaike Anna Hempenius ,&nbsp;Mieke C. Zwager ,&nbsp;Jeppe Thagaard ,&nbsp;Lorian Slagter-Menkema ,&nbsp;Henk J. Buikema ,&nbsp;Ellis Barbé ,&nbsp;Michael A. den Bakker ,&nbsp;Marjolein G.J. Heerema ,&nbsp;Elisabeth G.E. de Vries ,&nbsp;Carolina P. Schröder ,&nbsp;Nils A. ’t Hart ,&nbsp;Bert van der Vegt","doi":"10.1016/j.labinv.2025.104261","DOIUrl":"10.1016/j.labinv.2025.104261","url":null,"abstract":"<div><div>Trastuzumab-deruxtecan, an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2), improves overall survival in patients with breast cancer showing low or ultralow HER2 expression. Differences in HER2 test results have been reported between various HER2 assays and between primary tumors and metastases, but an objective comparison with incorporation of the new HER2-ultralow cutoff values is needed. This study aimed to assess the performance of 4 routine clinical-grade HER2 assays across and between primary tumors and their metastases using digital image analysis. Primary tumors and metastases from 193 patients with breast cancer who participated in the IMaging PAtients for Cancer drug selecTion—Metastatic Breast Cancer trial were incorporated into 6 tissue microarrays. Samples were stained by 4 laboratories using their routine HER2 immunohistochemistry protocols: 4B5 ultraView, 4B5 OptiView, SP3, and HercepTest (DG44). HER2 scores were determined using digital image analysis. The 4 HER2 assays showed significant differences in HER2 status in both primary tumors and metastases. Eighty-five matched primary tumors and metastases were analyzed to investigate concordance in HER2 status. Although no significant differences were found in HER2 scores between primary tumors and metastases for SP3 and both 4B5 assays, DG44 showed significantly higher HER2 scores in the metastasis (<em>P</em> = .004). Concordance between primary tumors and metastases was highest for 4B5 ultraView (69.4%), followed by SP3 (61.2%) and 4B5 OptiView (51.8%). DG44 showed the most variability, with only 36.5% of matched samples receiving the same HER2 category. DG44 identified a significantly higher proportion of HER2-(ultra)low cases and showed the most variability in HER2 status between matched primary tumors and metastases compared with 4B5 and SP3. The choice of HER2 assay can lead to discrepancies in HER2 status assessment, which could directly influence patient eligibility for trastuzumab-deruxtecan treatment.</div></div>","PeriodicalId":17930,"journal":{"name":"Laboratory Investigation","volume":"106 1","pages":"Article 104261"},"PeriodicalIF":4.2,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145573945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association Between CD4+/Programmed Cell Death 1+/CD153+ Cell Infiltration to the Aging Liver and Progression of Hepatic Steatosis in a Novel Metabolic Dysfunction–Associated Steatohepatitis Model Nishiura Mouse 新型MASH模型NI小鼠中CD4+/PD-1+/CD153+细胞浸润与肝脏衰老和肝脏脂肪变性进展的关系
IF 4.2 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-11-13 DOI: 10.1016/j.labinv.2025.104260
Nobuyoshi Suzuki , Hiroshi Nishiura , Misako Okuno , Mai Imasaka , Michihiko Sugimoto , Ikuo Nakamura , Toshiya Tachibana , Jiro Fujimoto , Masaki Ohmuraya
Metabolic dysfunction–associated steatohepatitis is one of the most important diseases, which progresses to hepatocellular carcinoma through hepatocellular dysfunction caused by steatosis and fibrosis. Recently, CD4+/programmed cell death 1 (PD-1)+/CD153+ cells (commonly referred to as senescence-associated T [SA-T] cells) have been identified as a senescence-associated secretory phenotype that produces chronic inflammation factors in a paracrine manner involved in osteopontin (OPN)-induced signal for the progression of steatosis in aging hepatocytes via antiapoptosis, alanine aminotransferase release, and so on. However, the detailed mechanisms are not fully elucidated. We identified a novel strain Nishiura (NI) mouse fed a normal diet that macroscopically showed yellowish orange discoloration of the liver at 36 weeks of age, followed by tumor-like masses at 48 weeks of age through a decrease in lineage−/CD34−/c-kit+/sca-1+ stem cells in the bone marrow and an increase in SA-T cells in the spleen at 24 weeks of age, infiltration of OPN+ or CD153+ cells in the PD-1+ liver at 36 weeks of age, and an increase in plasma OPN at 48 weeks of age. Conversely, SA-T cells, but not CD4+/PD-1+/CD153− cells, prepared from 36-week-old spleens of NI mice were transplanted into 12-week-old spleens of NI mice, but not into those of B6 mice, inducing severe hepatic steatosis and fibrosis at 36 weeks of age with an increase in OPN in the liver extract. Furthermore, in a cohort study, SA-T-cell rate in the biopsy specimen showed a positive correlation with the hepatitis activity index in patients with steatosis aged at least ≥60 years. In this paper, we discovered an association between CD4+/PD-1+/CD153+ cell infiltration to the aging liver and progression of hepatic steatosis in a novel metabolic dysfunction–associated steatohepatitis model NI mouse.
代谢紊乱相关性脂肪性肝炎(MASH)是一种重要的疾病,它通过脂肪变性和纤维化引起的肝细胞功能障碍发展为肝细胞癌。最近,CD4+/程序性细胞死亡1 (PD-1)+/CD153+细胞[通常被称为衰老相关T (SA-T)细胞]被确定为一种衰老相关的分泌表型,它通过抗凋亡、丙氨酸氨基转移酶(ALT)释放等方式,以旁分泌方式产生慢性炎症因子,参与骨桥蛋白(OPN)诱导的信号,促进衰老肝细胞脂肪变性的进展。然而,其具体机制尚未完全阐明。我们发现了一个异常的应变Nishiura (NI)老鼠喂食正常饮食,宏观上显示黄橙变色的肝脏在36周的年龄,其次是肿瘤在48周的年龄群众通过减少在天堂- / CD34 - / c - kit + /本来+干细胞在骨髓和增加SA-T细胞在脾脏在24周的时代,渗透OPN PD-1 + +或CD153 +细胞肝脏在36周的年龄,和增加血浆OPN在48周的年龄。相反,将36周龄NI小鼠脾脏制备的SA-T细胞(而不是CD4+/PD-1+/CD153-细胞)移植到12周龄NI小鼠脾脏中,而不是移植到B6小鼠脾脏中,在36周龄时引起严重的肝脏脂肪变性和纤维化,肝提取物中OPN增加。此外,在一项队列研究中,在60岁以上的脂肪变性患者中,活检标本中的SA-T细胞率与肝炎活动指数呈正相关。在本文中,我们在一种新型MASH模型NI小鼠中发现了CD4+/PD-1+/CD153+细胞浸润与肝脏衰老和肝脏脂肪变性进展之间的关联。
{"title":"Association Between CD4+/Programmed Cell Death 1+/CD153+ Cell Infiltration to the Aging Liver and Progression of Hepatic Steatosis in a Novel Metabolic Dysfunction–Associated Steatohepatitis Model Nishiura Mouse","authors":"Nobuyoshi Suzuki ,&nbsp;Hiroshi Nishiura ,&nbsp;Misako Okuno ,&nbsp;Mai Imasaka ,&nbsp;Michihiko Sugimoto ,&nbsp;Ikuo Nakamura ,&nbsp;Toshiya Tachibana ,&nbsp;Jiro Fujimoto ,&nbsp;Masaki Ohmuraya","doi":"10.1016/j.labinv.2025.104260","DOIUrl":"10.1016/j.labinv.2025.104260","url":null,"abstract":"<div><div>Metabolic dysfunction–associated steatohepatitis is one of the most important diseases, which progresses to hepatocellular carcinoma through hepatocellular dysfunction caused by steatosis and fibrosis. Recently, CD4+/programmed cell death 1 (PD-1)+/CD153+ cells (commonly referred to as senescence-associated T [SA-T] cells) have been identified as a senescence-associated secretory phenotype that produces chronic inflammation factors in a paracrine manner involved in osteopontin (OPN)-induced signal for the progression of steatosis in aging hepatocytes via antiapoptosis, alanine aminotransferase release, and so on. However, the detailed mechanisms are not fully elucidated. We identified a novel strain Nishiura (NI) mouse fed a normal diet that macroscopically showed yellowish orange discoloration of the liver at 36 weeks of age, followed by tumor-like masses at 48 weeks of age through a decrease in lineage−/CD34−/c-kit+/sca-1+ stem cells in the bone marrow and an increase in SA-T cells in the spleen at 24 weeks of age, infiltration of OPN+ or CD153+ cells in the PD-1+ liver at 36 weeks of age, and an increase in plasma OPN at 48 weeks of age. Conversely, SA-T cells, but not CD4+/PD-1+/CD153− cells, prepared from 36-week-old spleens of NI mice were transplanted into 12-week-old spleens of NI mice, but not into those of B6 mice, inducing severe hepatic steatosis and fibrosis at 36 weeks of age with an increase in OPN in the liver extract. Furthermore, in a cohort study, SA-T-cell rate in the biopsy specimen showed a positive correlation with the hepatitis activity index in patients with steatosis aged at least ≥60 years. In this paper, we discovered an association between CD4+/PD-1+/CD153+ cell infiltration to the aging liver and progression of hepatic steatosis in a novel metabolic dysfunction–associated steatohepatitis model NI mouse.</div></div>","PeriodicalId":17930,"journal":{"name":"Laboratory Investigation","volume":"106 1","pages":"Article 104260"},"PeriodicalIF":4.2,"publicationDate":"2025-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145530757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathologist-Artificial Intelligence Concordance in HER2 Interpretation for Advanced Biliary Tract Cancer: Intraobserver, Interobserver, and Human-Artificial Intelligence Variability 病理学家-人工智能(AI)在晚期胆道癌HER2解释中的一致性:观察者内部、观察者之间和人类-AI变异性。
IF 4.2 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-11-12 DOI: 10.1016/j.labinv.2025.104259
Hyunchul Kim , Jinhyung Heo , Soo Ick Cho , Beodeul Kang , Jung Sun Kim , Chan Kim , Chang Il Kwon , Min Je Sung , Seok-Pyo Shin , Seok Jeong Yang , Incheon Kang , Sung Hwan Lee , Chansik An , Seungeun Lee , Jin Woo Oh , Hee Yeon Kay , Jiwon Shin , Taebum Lee , Sanghoon Song , Sukjun Kim , Hong Jae Chon
Biliary tract cancer (BTC) is a rare, aggressive malignancy with a poor prognosis. HER2 is overexpressed in a subset of BTC patients, and recent advances in HER2-targeted agents are expanding therapeutic options. However, accurately assessing HER2 expression is challenging in BTC, especially at low levels. This study compared HER2 interpretations in advanced BTC by pathologists (H.K., J.H., and G.K.) using light microscopy (LM) and digital pathology (DP) and evaluated the potential of artificial intelligence (AI)–powered pathology in enhancing HER2-scoring consistency. A total of 309 HER2 immunohistochemistry slides were obtained from advanced BTC patients who received systemic therapy at the CHA Bundang Medical Center between 2019 and 2022. Three pathologists independently evaluated HER2 expression twice, once using LM and once using DP, with a washout period between evaluations. An AI–powered whole slide image analyzer evaluated HER2 expression. The ground truth was selected based on consensus among pathologists. Pathologists showed complete agreement on HER2 results in 62.1% of LM evaluations and 63.4% of DP evaluations. For intraobserver variability, the weighted kappa values ranged from 0.979 to 0.984, whereas interobserver variability ranged from 0.819 to 0.863 for LM and 0.820 to 0.876 for DP. The overall concordance rate of HER2 categories between the AI and the ground truth was 83.5%. Clinical factors such as HER2 expression level and specimen type significantly influenced intraobserver and interobserver variability, whereas histologic grade was a key factor affecting the AI model’s performance. In this study, we quantified intraobserver and interobserver variability in HER2 evaluation for BTC by pathologists and demonstrated that AI–powered HER2 scoring showed high concordance with pathologists’ evaluations. Because the clinical factors underlying the discrepancies in the results from the AI model and pathologists were different, the AI model is expected to help pathologists make more objective assessments of BTC HER2 readings in the future.
胆道癌(BTC)是一种罕见的侵袭性恶性肿瘤,预后差。HER2在一部分BTC患者中过度表达,HER2靶向药物的最新进展正在扩大治疗选择。然而,准确评估HER2在BTC中的表达具有挑战性,特别是在低水平时。本研究比较了病理学家使用光学显微镜(LM)和数字病理学(DP)对晚期BTC的HER2解释,并评估了人工智能(AI)驱动的病理学在增强HER2评分一致性方面的潜力。从2019年至2022年在CHA盆唐医疗中心接受全身治疗的晚期BTC患者中共获得309张HER2免疫组织化学切片。三名病理学家独立评估了两次HER2表达,一次使用LM,一次使用DP,两次评估之间有洗脱期。人工智能驱动的全幻灯片图像分析仪评估HER2表达。基本事实是根据病理学家的共识选出的。病理学家对62.1%的LM评估和63.4%的DP评估的HER2结果完全一致。对于观察者内变异性,加权kappa值为0.979 ~ 0.984,而观察者间变异性LM为0.819 ~ 0.863,DP为0.820 ~ 0.876。人工智能与地面真实HER2分类的总体符合率为83.5%。临床因素如HER2表达水平和标本类型显著影响观察者内部和观察者之间的变异性,而组织学分级是影响AI模型性能的关键因素。在这项研究中,我们量化了病理学家对BTC的HER2评估的观察者内部和观察者之间的可变性,并证明人工智能驱动的HER2评分与病理学家的评估高度一致。由于AI模型与病理学家结果差异的临床因素不同,AI模型有望在未来帮助病理学家对BTC HER2读数进行更客观的评估。
{"title":"Pathologist-Artificial Intelligence Concordance in HER2 Interpretation for Advanced Biliary Tract Cancer: Intraobserver, Interobserver, and Human-Artificial Intelligence Variability","authors":"Hyunchul Kim ,&nbsp;Jinhyung Heo ,&nbsp;Soo Ick Cho ,&nbsp;Beodeul Kang ,&nbsp;Jung Sun Kim ,&nbsp;Chan Kim ,&nbsp;Chang Il Kwon ,&nbsp;Min Je Sung ,&nbsp;Seok-Pyo Shin ,&nbsp;Seok Jeong Yang ,&nbsp;Incheon Kang ,&nbsp;Sung Hwan Lee ,&nbsp;Chansik An ,&nbsp;Seungeun Lee ,&nbsp;Jin Woo Oh ,&nbsp;Hee Yeon Kay ,&nbsp;Jiwon Shin ,&nbsp;Taebum Lee ,&nbsp;Sanghoon Song ,&nbsp;Sukjun Kim ,&nbsp;Hong Jae Chon","doi":"10.1016/j.labinv.2025.104259","DOIUrl":"10.1016/j.labinv.2025.104259","url":null,"abstract":"<div><div>Biliary tract cancer (BTC) is a rare, aggressive malignancy with a poor prognosis. HER2 is overexpressed in a subset of BTC patients, and recent advances in HER2-targeted agents are expanding therapeutic options. However, accurately assessing HER2 expression is challenging in BTC, especially at low levels. This study compared HER2 interpretations in advanced BTC by pathologists (H.K., J.H., and G.K.) using light microscopy (LM) and digital pathology (DP) and evaluated the potential of artificial intelligence (AI)–powered pathology in enhancing HER2-scoring consistency. A total of 309 HER2 immunohistochemistry slides were obtained from advanced BTC patients who received systemic therapy at the CHA Bundang Medical Center between 2019 and 2022. Three pathologists independently evaluated HER2 expression twice, once using LM and once using DP, with a washout period between evaluations. An AI–powered whole slide image analyzer evaluated HER2 expression. The ground truth was selected based on consensus among pathologists. Pathologists showed complete agreement on HER2 results in 62.1% of LM evaluations and 63.4% of DP evaluations. For intraobserver variability, the weighted kappa values ranged from 0.979 to 0.984, whereas interobserver variability ranged from 0.819 to 0.863 for LM and 0.820 to 0.876 for DP. The overall concordance rate of HER2 categories between the AI and the ground truth was 83.5%. Clinical factors such as HER2 expression level and specimen type significantly influenced intraobserver and interobserver variability, whereas histologic grade was a key factor affecting the AI model’s performance. In this study, we quantified intraobserver and interobserver variability in HER2 evaluation for BTC by pathologists and demonstrated that AI–powered HER2 scoring showed high concordance with pathologists’ evaluations. Because the clinical factors underlying the discrepancies in the results from the AI model and pathologists were different, the AI model is expected to help pathologists make more objective assessments of BTC HER2 readings in the future.</div></div>","PeriodicalId":17930,"journal":{"name":"Laboratory Investigation","volume":"106 1","pages":"Article 104259"},"PeriodicalIF":4.2,"publicationDate":"2025-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145513249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clues From Strange New Antigens: How Skin Responds to Nonself 来自奇怪的新抗原的线索:皮肤如何对非自我做出反应。
IF 4.2 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-11-11 DOI: 10.1016/j.labinv.2025.104258
Federico Repetto, Christine G. Lian, George F. Murphy
Skin is both the most immunogenic transplantable tissue and the easiest to observe clinically, making it an ideal system for understanding alloreactivity. We trace the concept of alloantigens from early transfusion work and the discovery of ABO and major histocompatibility complex/human leukocyte antigen to contemporary lessons learned by treating skin as both clinical grafts and experimental models. We then focus on 3 clinical arenas in which cutaneous alloimmunity is most visible: classic skin-graft rejection, rejection of vascularized composite allografts (VCAs), and graft-versus-host disease (GVHD). Across settings, acute injury is T-cell dominated but with different effector cell “provenance.” Target selection is likewise patterned rather than random. Basal keratinocytes and epidermal/follicular stem-cell niches may be early victims of cytotoxic and cytokine signals. In parallel, the vasculature emerges as a second critical target. Microvascular injury may accompany epithelial targeting in skin-graft and acute-VCA rejection, whereas chronic VCA rejection also shows macrovascular injury akin to inflammatory stages of arteriosclerosis culminating in dermal sclerosis with chronicity with similarities to chronic GVHD and scleroderma. Thus, many of these endpoints of various forms of alloreactivity mirror changes seen in “endogenous” dermatoses—fixed drug eruption for acute interface lesions and lupus/scleroderma for chronic fibrosing change—potentially revealing shared downstream pathways despite distinct triggers. We also highlight practical implications: site-oriented surveillance (notably oral/nasal mucosal biopsies that can outperform external skin early in VCA rejection), emerging tissue and circulating biomarkers, and therapeutic directions that pair immune regulation with tissue protection. Drawn from hundreds of biopsies across experimental models, skin allografts, VCAs, and GVHD, the unifying message is that who the effectors are (host vs donor), where they strike (stem-cell niches vs vasculature), and how those injuries unfold over time determine whether skin heals, scars, or fails—hopefully clarifying mechanisms and guiding more precise, tolerance-leaning, fibrosis-sparing care.
皮肤是最具免疫原性的可移植组织,也是最容易在临床上观察到的,使其成为了解同种异体反应性的理想系统。我们追溯异体抗原的概念,从早期输血工作和ABO和MHC/HLA的发现,到当代将皮肤作为临床移植和实验模型治疗的经验教训。然后,我们将重点放在皮肤同种异体免疫最明显的三个临床领域:经典皮肤移植排斥反应、血管化复合同种异体移植排斥反应(VCA)和移植物抗宿主病(GVHD)。在不同情况下,急性损伤以t细胞为主,但效应细胞“来源”不同。目标的选择同样是有规律的,而不是随机的。基底角化细胞和表皮/滤泡干细胞龛可能是细胞毒性和细胞因子信号的早期受害者。与此同时,脉管系统作为第二个关键目标出现。在皮肤移植和急性VCA排斥反应中,微血管损伤可能伴随上皮靶向;慢性VCA排斥也表现为大血管损伤,类似于动脉硬化的炎症阶段,最终导致皮肤硬化,其慢性与慢性GVHD和硬皮病相似。因此,许多不同形式的异体反应性的终点反映了“内源性”皮肤病的变化——急性界面病变的固定药物疹和慢性纤维化变化的狼疮/硬皮病——尽管有不同的触发因素,但潜在地揭示了共享的下游途径。我们还强调了实际意义:面向部位的监测(特别是口腔/鼻粘膜活检,在VCA排斥早期可以优于外部皮肤),新出现的组织和循环生物标志物,以及将免疫调节与组织保护相结合的治疗方向。从实验模型、皮肤同种异体移植、vca和GVHD的数百个活检中得出的统一信息是,效应器是谁(宿主vs供体),它们攻击的位置(干细胞壁龛vs脉管系统),以及这些损伤如何随着时间的推移决定皮肤是愈合、疤痕还是失败——希望能阐明机制,指导更精确、耐受性更强、避免纤维化的护理。
{"title":"Clues From Strange New Antigens: How Skin Responds to Nonself","authors":"Federico Repetto,&nbsp;Christine G. Lian,&nbsp;George F. Murphy","doi":"10.1016/j.labinv.2025.104258","DOIUrl":"10.1016/j.labinv.2025.104258","url":null,"abstract":"<div><div>Skin is both the most immunogenic transplantable tissue and the easiest to observe clinically, making it an ideal system for understanding alloreactivity. We trace the concept of alloantigens from early transfusion work and the discovery of ABO and major histocompatibility complex/human leukocyte antigen to contemporary lessons learned by treating skin as both clinical grafts and experimental models. We then focus on 3 clinical arenas in which cutaneous alloimmunity is most visible: classic skin-graft rejection, rejection of vascularized composite allografts (VCAs), and graft-versus-host disease (GVHD). Across settings, acute injury is T-cell dominated but with different effector cell “provenance.” Target selection is likewise patterned rather than random. Basal keratinocytes and epidermal/follicular stem-cell niches may be early victims of cytotoxic and cytokine signals. In parallel, the vasculature emerges as a second critical target. Microvascular injury may accompany epithelial targeting in skin-graft and acute-VCA rejection, whereas chronic VCA rejection also shows macrovascular injury akin to inflammatory stages of arteriosclerosis culminating in dermal sclerosis with chronicity with similarities to chronic GVHD and scleroderma. Thus, many of these endpoints of various forms of alloreactivity mirror changes seen in “endogenous” dermatoses—fixed drug eruption for acute interface lesions and lupus/scleroderma for chronic fibrosing change—potentially revealing shared downstream pathways despite distinct triggers. We also highlight practical implications: site-oriented surveillance (notably oral/nasal mucosal biopsies that can outperform external skin early in VCA rejection), emerging tissue and circulating biomarkers, and therapeutic directions that pair immune regulation with tissue protection. Drawn from hundreds of biopsies across experimental models, skin allografts, VCAs, and GVHD, the unifying message is that who the effectors are (host vs donor), where they strike (stem-cell niches vs vasculature), and how those injuries unfold over time determine whether skin heals, scars, or fails—hopefully clarifying mechanisms and guiding more precise, tolerance-leaning, fibrosis-sparing care.</div></div>","PeriodicalId":17930,"journal":{"name":"Laboratory Investigation","volume":"106 1","pages":"Article 104258"},"PeriodicalIF":4.2,"publicationDate":"2025-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145513196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to “Corrigendum to Tumor Necrosis Factor-α–Dependent Inflammation Upregulates High Mobility Group Box 1 To Induce Tumor Promotion and Anti–Programmed Cell Death Protein-1 Immunotherapy Resistance in Lung Adenocarcinoma” “肿瘤坏死因子-α-依赖性炎症上调高迁移率组1诱导肿瘤促进和抗程序性细胞死亡蛋白-1免疫治疗在肺腺癌中的耐药性”的更正:[实验室调查]105(11)(2025)104228]。
IF 4.2 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-11-04 DOI: 10.1016/j.labinv.2025.104255
Lifei Kang , Jingjing Cao , Wenli Guo , Xiaohui Cui , Yangxuan Wei , Jiayu Zhang , Feiran Liu , Chenyang Duan , Qiang Lin , Ping Lvx , Zhiyu Ni , Jing Zuo , Haitao Shen
{"title":"Corrigendum to “Corrigendum to Tumor Necrosis Factor-α–Dependent Inflammation Upregulates High Mobility Group Box 1 To Induce Tumor Promotion and Anti–Programmed Cell Death Protein-1 Immunotherapy Resistance in Lung Adenocarcinoma”","authors":"Lifei Kang ,&nbsp;Jingjing Cao ,&nbsp;Wenli Guo ,&nbsp;Xiaohui Cui ,&nbsp;Yangxuan Wei ,&nbsp;Jiayu Zhang ,&nbsp;Feiran Liu ,&nbsp;Chenyang Duan ,&nbsp;Qiang Lin ,&nbsp;Ping Lvx ,&nbsp;Zhiyu Ni ,&nbsp;Jing Zuo ,&nbsp;Haitao Shen","doi":"10.1016/j.labinv.2025.104255","DOIUrl":"10.1016/j.labinv.2025.104255","url":null,"abstract":"","PeriodicalId":17930,"journal":{"name":"Laboratory Investigation","volume":"105 12","pages":"Article 104255"},"PeriodicalIF":4.2,"publicationDate":"2025-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145452419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of Atypical and Subclonal p53 Immunohistochemistry Expression in Mismatch Repair Deficient and/or POLE-Mutant Endometrial Carcinomas with TP53 Mutation. 不典型和亚克隆p53免疫组织化学表达在错配修复缺陷和/或pole突变的TP53突变子宫内膜癌中的患病率
IF 4.2 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-11-01 Epub Date: 2025-07-17 DOI: 10.1016/j.labinv.2025.104216
Jing Wang, Yumeng Cai, Jun Wang, Jiuyuan Fang, Junyi Pang, Hui Zhang, Junliang Lu, Zijuan Zhang, Huanwen Wu, Zhiyong Liang

p53 Immunohistochemistry (IHC) is a reliable surrogate for determining TP53 mutation status in endometrial carcinomas (ECs). However, the correlation of p53 IHC patterns and TP53 mutation characteristics in mismatch repair deficiency (MMRd) and/or POLE-mutant ECs was not comprehensively investigated. In this study, we identified 4 p53 expression patterns in 40 MMRd and/or POLE-mutant ECs with TP53 mutations. Thirteen cases (33%) displayed a wild-type pattern. Nine cases (23%) showed atypical pattern, characterized by the presence of eye-catching clustered cells with strong nuclear staining or weak-to-moderate cytoplasmic staining, which were patchily distributed with blurred boundaries. Fourteen cases (35%) demonstrated subclonal pattern with distinct regions of wild-type and mutation-type staining, of which 3 cases were originally misdiagnosed as "mixed EC." Only 4 (10%) cases exhibited typical aberrant pattern. Tumors with wild-type and atypical patterns were predominantly associated with MMRd and POLE mutations, respectively. Among 52 TP53 mutations identified, 75% were missense and 25% were truncating, predominantly in DNA-binding domain. Gain-of-function missense mutations were more frequent in cases with subclonal patterns, whereas non-gain-of-function missense mutations predominated in wild-type or atypical patterns. Concurrent mutations were present in 25% of cases and were more common in aberrant or atypical patterns. Interestingly, 2 POLE wild-type cases with subclonal MMR expression showed p53 overexpression across the entire tumor, complicating molecular subtyping. These findings highlight the prevalence of atypical and subclonal p53 expression patterns in MMRd and/or POLE-mutant ECs with TP53 mutations, aiding in accurate IHC interpretation and thus more precise EC histological and molecular classification.

p53免疫组化(IHC)是确定子宫内膜癌(ECs)中TP53突变状态的可靠替代方法。然而,在错配修复缺陷(MMRd)和/或pole突变ec中,p53 IHC模式与TP53突变特征的相关性尚未得到全面研究。在这项研究中,我们在40例TP53突变的MMRd和/或pole突变ec中发现了四种p53表达模式。13例(33%)表现为野生型。9例(23%)表现不典型,表现为明显的聚集性细胞,核染色强或细胞质染色弱至中度,斑状分布,边界模糊。14例(35%)表现为亚克隆型,具有不同区域的野生型和突变型染色,其中3例最初被误诊为“混合型EC”。只有4例(10%)表现出典型的异常模式。野生型和非典型型肿瘤分别主要与MMRd和POLE突变相关。在鉴定的52个TP53突变中,75%是错义突变,25%是截断突变,主要发生在DNA结合域。功能获得(GOF)错义突变在亚克隆模式中更为常见,而非GOF错义突变在野生型或非典型模式中占主导地位。并发突变存在于25%的病例中,在异常或非典型模式中更为常见。有趣的是,两个具有亚克隆MMR表达的POLE野生型病例显示p53在整个肿瘤中过表达,使分子分型复杂化。这些发现强调了非典型和亚克隆p53表达模式在MMRd和/或极突变的TP53突变EC中普遍存在,有助于准确的免疫组化解释,从而更精确地进行EC的组织学和分子分类。
{"title":"Prevalence of Atypical and Subclonal p53 Immunohistochemistry Expression in Mismatch Repair Deficient and/or POLE-Mutant Endometrial Carcinomas with TP53 Mutation.","authors":"Jing Wang, Yumeng Cai, Jun Wang, Jiuyuan Fang, Junyi Pang, Hui Zhang, Junliang Lu, Zijuan Zhang, Huanwen Wu, Zhiyong Liang","doi":"10.1016/j.labinv.2025.104216","DOIUrl":"10.1016/j.labinv.2025.104216","url":null,"abstract":"<p><p>p53 Immunohistochemistry (IHC) is a reliable surrogate for determining TP53 mutation status in endometrial carcinomas (ECs). However, the correlation of p53 IHC patterns and TP53 mutation characteristics in mismatch repair deficiency (MMRd) and/or POLE-mutant ECs was not comprehensively investigated. In this study, we identified 4 p53 expression patterns in 40 MMRd and/or POLE-mutant ECs with TP53 mutations. Thirteen cases (33%) displayed a wild-type pattern. Nine cases (23%) showed atypical pattern, characterized by the presence of eye-catching clustered cells with strong nuclear staining or weak-to-moderate cytoplasmic staining, which were patchily distributed with blurred boundaries. Fourteen cases (35%) demonstrated subclonal pattern with distinct regions of wild-type and mutation-type staining, of which 3 cases were originally misdiagnosed as \"mixed EC.\" Only 4 (10%) cases exhibited typical aberrant pattern. Tumors with wild-type and atypical patterns were predominantly associated with MMRd and POLE mutations, respectively. Among 52 TP53 mutations identified, 75% were missense and 25% were truncating, predominantly in DNA-binding domain. Gain-of-function missense mutations were more frequent in cases with subclonal patterns, whereas non-gain-of-function missense mutations predominated in wild-type or atypical patterns. Concurrent mutations were present in 25% of cases and were more common in aberrant or atypical patterns. Interestingly, 2 POLE wild-type cases with subclonal MMR expression showed p53 overexpression across the entire tumor, complicating molecular subtyping. These findings highlight the prevalence of atypical and subclonal p53 expression patterns in MMRd and/or POLE-mutant ECs with TP53 mutations, aiding in accurate IHC interpretation and thus more precise EC histological and molecular classification.</p>","PeriodicalId":17930,"journal":{"name":"Laboratory Investigation","volume":" ","pages":"104216"},"PeriodicalIF":4.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Laboratory Investigation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1